Literature DB >> 6112024

Phenelzine and exposure in the treatment of phobias.

C Solyom, L Solyom, Y LaPierre, J Pecknold, L Morton.   

Abstract

A double-blind study was carried out on 40 agoraphobic and socially phobic patients, matched, then randomly assigned to one of four treatment groups; phenelzine-exposure, phenelzine-no exposure, placebo-exposure, and placebo-no exposure. Exposure consisted of encouraging the patient to face the phobic situation a predetermined number of times. Assessments, made at the beginning and end of 8 weeks of therapy and 8 weeks thereafter, showed that the phobia ratings of groups decreased significantly. The combined exposure group improved significantly more than the combined no exposure group during treatment. At 8 weeks follow-up there was some deterioration in the phenelzine-exposure and placebo-no exposure groups. Exposure, with or without phenelzine, was the superior treatment modality. The antiphobic effect of phenelzine was not supported, although it seemed to reduce subjective anxiety during exposure experiences. The possibility that effect of phenelzine is dose-related is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112024

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  11 in total

Review 1.  Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia.

Authors:  T A Furukawa; N Watanabe; R Churchill
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Social phobias: behavioural and pharmacotherapy.

Authors:  R T Reesal; H Bajramovic
Journal:  Can Fam Physician       Date:  1989-05       Impact factor: 3.275

Review 3.  Overview of panic disorder.

Authors:  J C Ballenger
Journal:  Trans Am Clin Climatol Assoc       Date:  1994

4.  Panic disorder.

Authors:  I Marks
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-23

Review 5.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

6.  MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.

Authors:  I M van Vliet; H G Westenberg; J A Den Boer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  A risk-benefit assessment of pharmacological treatments for panic disorder.

Authors:  J A Bennett; M Moioffer; S P Stanton; M Dwight; P E Keck
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

Review 8.  Recent developments in the psychopharmacology of social phobia.

Authors:  J A Den Boer; I M van Vliet; H G Westenberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

9.  Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine.

Authors:  I M van Vliet; J A den Boer; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

10.  Nonpharmacological treatments for anxiety disorders.

Authors:  Jean Cottraux
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.